Nivolumab 240 mg

DRUG2 trials

Sponsors

Michael B. Atkins, MD, Weill Medical College of Cornell University

Conditions

Advanced Renal Cell CarcinomaGastroesophageal Adenocarcinoma

Phase 2

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

CompletedNCT03117309

Michael B. Atkins, MDAdvanced Renal Cell Carcinoma

Start: 2017-04-24End: 2025-01-23Updated: 2025-07-10

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Active, not recruitingNCT04021108

Weill Medical College of Cornell UniversityGastroesophageal Adenocarcinoma

Start: 2019-07-22End: 2026-06-30Updated: 2025-06-24

Related Papers

Co-expression network-based analysis of gene programs contributing to immune checkpoint inhibitor (ICI) resistance in renal cell carcinoma (RCC).

Journal of Clinical Oncology2025-05-28

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery2025-02-2422 citations

Multicenter randomized phase II study of short course FOLFOX + nivolumab (Nivo) followed by maintenance Nivo +/- radiation (RT) in the first line treatment of metastatic or unresectable gastroesophageal adenocarcinoma (mGEA).

Journal of Clinical Oncology2024-06-01

1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma

Regular and Young Investigator Award Abstracts2023-10-31

Abstract B013: T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockade

Cancer Research2023-08-15

Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.

Journal of Clinical Oncology2023-06-014 citations

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Journal for ImmunoTherapy of Cancer2023-03-0128 citations

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology2023-02-205 citations

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.

Journal of Clinical Oncology2022-02-166 citations

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).

Journal of Clinical Oncology2021-05-208 citations

A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers.

Journal of Clinical Oncology2021-05-20

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).

Journal of Clinical Oncology2020-05-2056 citations